YTTERBIUM YB 169 DTPA
LOE Approachingpentetate calcium trisodium yb-169
NDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ytterbium Yb 169 DTPA (Pentetate Calcium Trisodium Yb-169) is a radiopharmaceutical diagnostic agent administered via injection. It is used for renal imaging and kidney function assessment in nuclear medicine procedures. The agent localizes in the kidneys, enabling visualization of renal perfusion and function.
LOE Approaching
This legacy diagnostic agent faces imminent loss of exclusivity with minimal current commercial infrastructure, suggesting limited team expansion and a focus on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, career opportunities on this product are severely limited. This assignment represents a defensive, winding-down role rather than a growth opportunity, suitable only for professionals interested in legacy product management or regulatory compliance work.
Regulatory Affairs SpecialistMarket Access Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.